Skip to content

Abstract 9771: Cardiovascular and Mortality Outcomes Associated with GLP-1 Receptor Agonists Among Adults with Prediabetes: A Propensity-Matched Real-World Cohort Study

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: Prediabetes is a growing global health burden associated with elevated cardiovascular risk well before overt diabetes. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) confer cardiovascular benefit in type 2 diabetes and obesity, real-world data in overweight or obese adults with prediabetes are limited. Hypothesis: GLP-1RA therapy is associated with lower risks of cardiovascular, cardiorenal, pulmonary vascular, thromboembolic, and mortality outcomes in overweight or obese adults with prediabetes and no diabetes mellitus. Methods: Using the TriNetX Global Collaborative Network (168 healthcare organizations), we identified adults ≥18 years with overweight/obesity (ICD-10 E66) and prediabetes (R73.03), without diabetes mellitus, from January 1, 2018 onward. GLP-1RA users were compared with non-users. Propensity-score matching (1:1, nearest-neighbor) on 47 covariates, demographics, 22 comorbidities, 16 medication classes, and laboratory values (BMI, HbA1c, fasting and serum glucose), yielded 144,130 matched pairs (Figure 1). For ten incident outcomes. hazard ratios (HR) from Cox proportional-hazards models and risk ratios (RR) from measure-of-association analyses were calculated, excluding patients with each outcome before index: all-cause mortality, myocardial infarction (MI), ischemic stroke, heart failure (HF), atrial fibrillation/flutter (AF), chronic kidney disease (CKD), peripheral vascular disease (PVD), atherosclerosis, pulmonary embolism (PE), and pulmonary hypertension (PH). Results: The matched cohort included 288,260 patients (mean age 50.9 years; 73.0% female; mean BMI 39.3 kg/m 2 ; mean HbA1c 5.8%); hypertension, dyslipidemia, obstructive sleep apnea, and ischemic heart disease were present in 56.0%, 58.5%, 31.1%, and 11.5%, respectively. Mean follow-up was 588 days (GLP-1RA) and 908 days (non-users). Compared with matched non-users, GLP-1RA use was associated with significantly lower risks of all-cause mortality (HR 0.261, 95% CI 0.236-0.287), myocardial infarction (HR 0.642, 95% CI 0.581-0.710), ischemic stroke (HR 0.689, 95% CI 0.625-0.758), heart failure (HR 0.664, 95% CI 0.626-0.705), and chronic kidney disease (HR 0.757, 95% CI 0.719-0.797) (all p<0.001). Consistent reductions were observed across additional vascular and thromboembolic outcomes (Figure 2). Conclusions: Among overweight or obese adults with prediabetes and no established diabetes mellitus, GLP-1RA use was associated with lower risks of mortality and multiple cardiovascular and cardiorenal outcomes. Given the observational nature of this study, residual confounding cannot be excluded. Prospective studies are needed to determine whether GLP-1RAs confer cardiovascular and survival benefits in high-risk prediabetic populations.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.